Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β

Bapineuzumab (AAB-001) and its derivative (AAB-003) are humanized versions of the anti-A beta murine antibody 3D6 and are immunotherapy candidates in Alzheimer's disease. The common Fab fragment of these immunotherapies has been expressed, purified and crystallized in complex with beta-amyloid peptides (residues 1-8 and 1-28). Diffraction data at high resolution were acquired from crystals of Fab-A beta(8) (2.0 angstrom) and Fab-A beta(28) (2.2 angstrom) complexes at the Australian Synchrotron. Both crystal forms belonged to the primitive orthorhombic space group P2(1)22(1).